Genomic Test May Spare More Patients With Node-Positive Breast Cancer From Chemo

(MedPage Today) -- The phase III OPTIMA trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, showed that some patients with high-risk, early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer...